Please login to the form below
checkpoint inhibitor
This page shows the latest checkpoint inhibitor news and features for those working in and with pharma, biotech and healthcare.
Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn
administered selective complement component 5a receptor inhibitor. ... In addition to Tavneos, the acquisition gives Amgen access to three early-stage drug candidates that target chemoattractant receptors in other inflammatory diseases and an oral
Latest news
-
Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment
The PD-1 inhibitor demonstrated a statistically significant benefit in recurrence-free survival. ... Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, designed to help the natural T-cell response to cancer, by improving the body’s
-
Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, designed to try to help the natural T-cell response to cancer, by improving the body’s ability to recognise ... In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to
-
Amgen’s Lumakras shows promising results for patients with non-small cell lung cancer
doublet chemotherapy and checkpoint inhibitor therapy. ... meeting. "We are grateful to all of the investigators and patients who participated in this first randomised, controlled clinical trial of a KRAS inhibitor.".
-
Amgen to acquire ChemoCentryx in $3.7bn cash deal
Tavneos is an orally administered selective complement component 5a receptor inhibitor. ... As well as Tavneos, ChemoCentryx has three early-stage drug candidates that target chemoattractant receptors in other inflammatory diseases and an oral checkpoint
-
Sanofi and Innovent Biologics to develop oncology drugs for patients in China
These include its phase 3 SAR408701 (tusamitamab ravtansine, anti-CEACAM5 antibody-drug conjugate) and its phase 2 SAR444245 (non-alpha IL-2), combining with Tyvyt (sintilimab), the leading checkpoint inhibitor in
More from news
Approximately 11 fully matching, plus 225 partially matching documents found.
Latest Intelligence
-
Putting the ovation into innovation: trends from ESMO
Based on the results we have seen with immune checkpoint inhibitors (ICIs), it will be interesting to see how T-DXd performs in the neoadjuvant setting. ... However, the data is very impressive in patients no longer responding to checkpoint inhibitor
-
Surviving cancer: a new era for patients
Immune checkpoint inhibitors. Immune (T) cells exhibit proteins that can turn an immune response on or off, called checkpoint proteins. ... Several checkpoint inhibitor drugs have been developed showing strong event- free survival and PFS rates, opening
-
Can protein degraders unlock ‘undruggable’ drug targets?
These compounds could be used to tackle resistance to kinase inhibitor drugs, for example. ... The lead project in that partnership is an inhibitor of CBL-B, an immune checkpoint that is still in preclinical development and will migrate to Bristol-Myers
-
20 for 2020 – Five pharma companies to watch
checkpoint inhibitor Imfinzi such as the POSEIDON trial in first-line NSCLC, are key newsflow events this year. ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better
-
Immuno-oncology in 2019: the rapid evolution continues
cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... 50%. The true figure for patients treated with checkpoint inhibitor monotherapy achieving durable and meaningful clinical responses is in fact nearer 20%.
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
This includes the approval of Merck’s checkpoint inhibitor Keytruda (pembrolizumab), which has been approved in over 25 indications across 16 tumour types.
-
New hires at Crescendo, Healx and Galecto
oncology. Prior to Crescendo, Hashimoto (pictured below, right) led the clinical development of a checkpoint inhibitor in renal cell carcinoma at Roche, and held responsibility for multiple.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
Checkpoint inhibitor-refractory disease represents a growing population and an emerging therapeutic challenge. ... trocar. Further, TAVO has already proven to show robust efficacy in difficult-to-treat patient populations, including metastatic melanoma
-
Highlights in haematologic malignancy from ASH 2018
Initial findings from small groups of patients suggest CD19-directed CAR T-cell therapy, plus ibrutinib or a checkpoint inhibitor, can enhance responses and/or reduce toxicity in difficult-to-treat
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- Creabilis names Catherine Moukheibir as chairman of the board
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- MIT researchers develop AI model to detect future lung cancer risk
- World Health Organization releases latest set of COVID-19 guidelines
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
